Aligos Therapeutics, Inc.

NasdaqCM:ALGS Stock Report

Market Cap: US$51.8m

Aligos Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ALGS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders113,8941.85%
Public Companies441,0377.17%
VC/PE Firms444,1107.22%
Institutions1,181,76619.2%
Hedge Funds1,216,13619.8%
General Public2,756,63944.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 65.8%.

Top Shareholders

Top 25 shareholders own 54.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.61%
Woodline Partners LP
468,199US$3.9m-9.67%0.02%
7.22%
Deep Track Capital, LP
444,110US$3.7m0%0.07%
7.17%
Roche Holding AG
441,037US$3.7m0%no data
6.7%
Alyeska Investment Group, L.P.
412,000US$3.5m0%0.01%
5.46%
Sio Capital Management, LLC
335,937US$2.8m-5.62%0.63%
3.3%
Readystate Asset Management LP
203,113US$1.7m48.5%0.18%
3.06%
Armistice Capital LLC
188,438US$1.6m0%0.04%
2.79%
The Vanguard Group, Inc.
171,689US$1.4m22.8%no data
2.28%
Adage Capital Management, L.P.
140,000US$1.2m0%no data
1.38%
Lawrence Blatt
84,822US$713.4k0%no data
1.35%
Baker Bros. Advisors LP
83,055US$698.5k0%no data
1.24%
Hillhouse Investment Management, Ltd.
76,247US$641.2k0%no data
0.9%
LPL Financial LLC
55,120US$463.6k83.1%no data
0.89%
Renaissance Technologies LLC
55,019US$462.7k4.71%no data
0.77%
Geode Capital Management, LLC
47,080US$395.9k38.3%no data
0.63%
Two Sigma Investments, LP
38,995US$328.0k223%no data
0.5%
Squarepoint OPS LLC
30,493US$256.4k64%no data
0.26%
UBS Asset Management AG
16,182US$136.1k490%no data
0.26%
Julian Symons
15,762US$132.6k0%no data
0.21%
BlackRock, Inc.
13,040US$109.7k0%no data
0.18%
Morgan Stanley
11,284US$94.9k182%no data
0.17%
Citadel Advisors LLC
10,310US$86.7k-32.2%no data
0.16%
Susquehanna International Group, LLP
10,107US$85.0k0%no data
0.16%
Northcrest Asset Management LLC
10,000US$84.1k0%no data
0.12%
James Scopa
7,323US$61.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 14:22
End of Day Share Price 2026/01/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aligos Therapeutics, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Antonio ArceH.C. Wainwright & Co.
Patrick TrucchioH.C. Wainwright & Co.
Yuxi DongJefferies LLC